Lingfeng Wu

A pilot prospective study of tislelizumab and axitinib combined with stereotactic body radiation therapy for oligometastatic renal cell carcinoma

<title>Abstract</title> Background The aim of this study is to investigate the efficacy and safety of tislelizumab and axitinib combined with SBRT in the treatment of omRCC. Methods Eligible pts had oligometastases (≤ 5 leisions) and ≤ 1 prior systemic therapy. All patients recei...